Cargando…
Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry
Data from real-world use of new systemic treatments in atopic dermatitis (AD) is important for assessing safety and efficacy. The aim of this study is to describe the baseline characteristics of adult patients with moderate-to-severe AD enrolled in the Danish nationwide Severe and ChRonic Atopic der...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631293/ https://www.ncbi.nlm.nih.gov/pubmed/35670330 http://dx.doi.org/10.2340/actadv.v102.915 |
_version_ | 1784823787318935552 |
---|---|
author | LARSEN, Henrik H. P. VITTRUP, Ida RUGE, Iben F. ELBERLING, Jesper SKOV, Lone IBLER, Kristina JEMEC, Gregor B. E. MORTZ, Charlotte G. BACH, Rasmus O. BINDSLEV-JENSEN, Carsten DALAGER, Maiken G. AGNER, Tove DELEURAN, Mette VESTERGAARD, Christian THYSSEN, Jacob P. |
author_facet | LARSEN, Henrik H. P. VITTRUP, Ida RUGE, Iben F. ELBERLING, Jesper SKOV, Lone IBLER, Kristina JEMEC, Gregor B. E. MORTZ, Charlotte G. BACH, Rasmus O. BINDSLEV-JENSEN, Carsten DALAGER, Maiken G. AGNER, Tove DELEURAN, Mette VESTERGAARD, Christian THYSSEN, Jacob P. |
author_sort | LARSEN, Henrik H. P. |
collection | PubMed |
description | Data from real-world use of new systemic treatments in atopic dermatitis (AD) is important for assessing safety and efficacy. The aim of this study is to describe the baseline characteristics of adult patients with moderate-to-severe AD enrolled in the Danish nationwide Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH) database, between October 2017 and August 2021. A total of 282 adult patients were included. Most (62%) were men, the median age at baseline was 43 years (interquartile range (IQR) 29–54 years), and median age at onset of AD was 1 year (IQR 0–6 years). The median Eczema Area and Severity Index at treatment initiation was 19.1 (IQR 11.9–25.7); median Patient Oriented Eczema Measure 21.0 (IQR 16.0–25.0); median Dermatology Life Quality Index 13.0 (IQR 7.0–19.0); and median itch and sleep numerical rating scale scores 8.0 (IQR 6.0–9.0) and 6.0 (IQR 4.0–8.0). Differences were found between the sexes. This registry will provide a source for future efficacy and safety studies. |
format | Online Article Text |
id | pubmed-9631293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Society for Publication of Acta Dermato-Venereologica |
record_format | MEDLINE/PubMed |
spelling | pubmed-96312932022-11-18 Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry LARSEN, Henrik H. P. VITTRUP, Ida RUGE, Iben F. ELBERLING, Jesper SKOV, Lone IBLER, Kristina JEMEC, Gregor B. E. MORTZ, Charlotte G. BACH, Rasmus O. BINDSLEV-JENSEN, Carsten DALAGER, Maiken G. AGNER, Tove DELEURAN, Mette VESTERGAARD, Christian THYSSEN, Jacob P. Acta Derm Venereol Original Article Data from real-world use of new systemic treatments in atopic dermatitis (AD) is important for assessing safety and efficacy. The aim of this study is to describe the baseline characteristics of adult patients with moderate-to-severe AD enrolled in the Danish nationwide Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH) database, between October 2017 and August 2021. A total of 282 adult patients were included. Most (62%) were men, the median age at baseline was 43 years (interquartile range (IQR) 29–54 years), and median age at onset of AD was 1 year (IQR 0–6 years). The median Eczema Area and Severity Index at treatment initiation was 19.1 (IQR 11.9–25.7); median Patient Oriented Eczema Measure 21.0 (IQR 16.0–25.0); median Dermatology Life Quality Index 13.0 (IQR 7.0–19.0); and median itch and sleep numerical rating scale scores 8.0 (IQR 6.0–9.0) and 6.0 (IQR 4.0–8.0). Differences were found between the sexes. This registry will provide a source for future efficacy and safety studies. Society for Publication of Acta Dermato-Venereologica 2022-08-24 /pmc/articles/PMC9631293/ /pubmed/35670330 http://dx.doi.org/10.2340/actadv.v102.915 Text en © 2022 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license |
spellingShingle | Original Article LARSEN, Henrik H. P. VITTRUP, Ida RUGE, Iben F. ELBERLING, Jesper SKOV, Lone IBLER, Kristina JEMEC, Gregor B. E. MORTZ, Charlotte G. BACH, Rasmus O. BINDSLEV-JENSEN, Carsten DALAGER, Maiken G. AGNER, Tove DELEURAN, Mette VESTERGAARD, Christian THYSSEN, Jacob P. Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry |
title | Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry |
title_full | Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry |
title_fullStr | Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry |
title_full_unstemmed | Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry |
title_short | Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry |
title_sort | severe and chronic atopic dermatitis treatment cohort (scratch): a danish real-world evidence atopic dermatitis treatment registry |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631293/ https://www.ncbi.nlm.nih.gov/pubmed/35670330 http://dx.doi.org/10.2340/actadv.v102.915 |
work_keys_str_mv | AT larsenhenrikhp severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT vittrupida severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT rugeibenf severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT elberlingjesper severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT skovlone severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT iblerkristina severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT jemecgregorbe severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT mortzcharlotteg severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT bachrasmuso severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT bindslevjensencarsten severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT dalagermaikeng severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT agnertove severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT deleuranmette severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT vestergaardchristian severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry AT thyssenjacobp severeandchronicatopicdermatitistreatmentcohortscratchadanishrealworldevidenceatopicdermatitistreatmentregistry |